These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20955498)

  • 1. Barriers to starting ART and how they can be overcome: individual and operational factors associated with early and late start of treatment.
    Parkes-Ratanshi R; Bufumbo L; Nyanzi-Wakholi B; Levin J; Grosskurth H; Lalloo DG; Kamali A
    Trop Med Int Health; 2010 Nov; 15(11):1347-56. PubMed ID: 20955498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Test and treat: the early experiences in a clinic serving women at high risk of HIV infection in Kampala.
    Mbonye M; Seeley J; Nalugya R; Kiwanuka T; Bagiire D; Mugyenyi M; Namale G; Mayanja Y; Kamali A
    AIDS Care; 2016; 28 Suppl 3():33-8. PubMed ID: 27421050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Side effects' are 'central effects' that challenge retention in HIV treatment programmes in six sub-Saharan African countries: a multicountry qualitative study.
    Renju J; Moshabela M; McLean E; Ddaaki W; Skovdal M; Odongo F; Bukenya D; Wamoyi J; Bonnington O; Seeley J; Zaba B; Wringe A
    Sex Transm Infect; 2017 Jul; 93(Suppl 3):. PubMed ID: 28736390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predictive of successful retention in care among HIV-infected men in a universal test-and-treat setting in Uganda and Kenya: A mixed methods analysis.
    Brown LB; Getahun M; Ayieko J; Kwarisiima D; Owaraganise A; Atukunda M; Olilo W; Clark T; Bukusi EA; Cohen CR; Kamya MR; Petersen ML; Charlebois ED; Havlir DV; Camlin CS
    PLoS One; 2019; 14(1):e0210126. PubMed ID: 30673744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and predictors for late start of antiretroviral therapy in primary care clinics, Kampala, Uganda.
    Sendagire I; Cobelens F; Kambugu A; Konde-Lule J; van der Loeff MS
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):e33-9. PubMed ID: 22820807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What influences uptake and early adherence to Option B+ (lifelong antiretroviral therapy among HIV positive pregnant and breastfeeding women) in Central Uganda? A mixed methods study.
    Mukose AD; Bastiaens H; Makumbi F; Buregyeya E; Naigino R; Musinguzi J; Van Geertruyden JP; Wanyenze RK
    PLoS One; 2021; 16(5):e0251181. PubMed ID: 33951109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa.
    Iwuji C; Chimukuche RS; Zuma T; Plazy M; Larmarange J; Orne-Gliemann J; Siedner M; Shahmanesh M; Seeley J
    PLoS One; 2020; 15(9):e0239513. PubMed ID: 32970730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction of estimates of retention in care among a cohort of HIV-positive patients in Uganda in the period before starting ART: a sampling-based approach.
    Nyakato P; Kiragga AN; Kambugu A; Bradley J; Baisley K
    BMJ Open; 2018 Apr; 8(4):e017487. PubMed ID: 29678963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa.
    Boyer S; Iwuji C; Gosset A; Protopopescu C; Okesola N; Plazy M; Spire B; Orne-Gliemann J; McGrath N; Pillay D; Dabis F; Larmarange J;
    AIDS Care; 2016; 28 Suppl 3(Suppl 3):39-51. PubMed ID: 27421051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.
    ; Keiser O; Anastos K; Schechter M; Balestre E; Myer L; Boulle A; Bangsberg D; Touré H; Braitstein P; Sprinz E; Nash D; Hosseinipour M; Dabis F; May M; Brinkhof MW; Egger M
    Trop Med Int Health; 2008 Jul; 13(7):870-9. PubMed ID: 18373510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial.
    Amanyire G; Semitala FC; Namusobya J; Katuramu R; Kampiire L; Wallenta J; Charlebois E; Camlin C; Kahn J; Chang W; Glidden D; Kamya M; Havlir D; Geng E
    Lancet HIV; 2016 Nov; 3(11):e539-e548. PubMed ID: 27658873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention in care of HIV-infected children from HIV test to start of antiretroviral therapy: systematic review.
    Mugglin C; Wandeler G; Estill J; Egger M; Bender N; Davies MA; Keiser O
    PLoS One; 2013; 8(2):e56446. PubMed ID: 23437135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coverage of highly active antiretroviral therapy among postpartum women in Malawi.
    Kumwenda J; Matchere F; Mataya R; Chen S; Mipando L; Li Q; Kumwenda NI; Taha TE
    Int J STD AIDS; 2011 Jul; 22(7):368-72. PubMed ID: 21729953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa.
    Schomaker M; Egger M; Ndirangu J; Phiri S; Moultrie H; Technau K; Cox V; Giddy J; Chimbetete C; Wood R; Gsponer T; Bolton Moore C; Rabie H; Eley B; Muhe L; Penazzato M; Essajee S; Keiser O; Davies MA;
    PLoS Med; 2013 Nov; 10(11):e1001555. PubMed ID: 24260029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
    Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
    Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
    Siegfried N; Uthman OA; Rutherford GW
    Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries.
    Ahmed S; Autrey J; Katz IT; Fox MP; Rosen S; Onoya D; Bärnighausen T; Mayer KH; Bor J
    Soc Sci Med; 2018 Sep; 213():72-84. PubMed ID: 30059900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.